PANORAMIC COVID-19 treatment trial recruits 20,000 participants
The University of Oxford’s PANORAMIC trial has become the world’s largest study of community-based COVID-19 treatments, recruiting over 21,800 volunteers.
The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of COVID-19 In the Community (PANORAMIC) is being led by the university with support from the NIHR Clinical Research Network Thames Valley and South Midlands.
Over 640 volunteers from Oxfordshire have taken part so far.
The UK-wide study is evaluating whether drugs given in early stages of COVID-19 can help people at higher risk of complications recover faster and avoid hospital admission.
Participants are given molnupiravir or a placebo dummy drug. Further antiviral treatments will also be investigated.
Volunteers aged over 50 or over 18 with a pre-existing condition, with COVID-19 symptoms beginning in the last five days and a positive PCR or LFT test are taking part.
Professor Chris Butler, PANORAMIC Chief Investigator, said: “We have been humbled by the huge support we have received from so many members of the UK public, who have generously shared their experiences of COVID-19 in the PANORAMIC trial.
“The contribution of each and every one is critically important in producing the evidence we need for the NHS to use these promising treatments to their best effect. We also really appreciate those who have joined PANORAMIC staying with us over the longer term so we can collect data on the effectiveness of the treatments for continuing and relapsing symptoms.”
Read more on the trial website.
